查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1555475

抗真菌藥物市場，按藥物類別、按適應症、按給藥途徑、按感染類型、按配銷通路、按國家和地區 - 2024-2032 年行業分析、市場規模、市場佔有率和預測

Antifungal Drugs Market, By Drug Class, By Indication, By Route of Administration, By Infection Type, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 388 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告要點

2023年抗真菌藥物市場規模為156.7823億美元，2024年至2032年複合年成長率為3.79%。

抗真菌藥物市場-市場動態

真菌感染的日益流行預計將推動市場的成長

真菌感染，包括念珠菌病、曲霉菌病和隱球菌病，越來越普遍，特別是在免疫系統受損的個體中，例如患有愛滋病毒/愛滋病、癌症或接受器官移植的人。這些感染頻率的上升，加上人們認知的提高和診斷工具的可用性，正在推動對有效抗真菌療法的需求。根據美國疾病管制與預防中心的數據，每年有超過 75,000 人次因真菌疾病住院治療，近 900 萬人次門診就診。此外，抗真菌治療的持續研究和開發，包括新藥類別和創新配方的鑑定，帶來了巨大的市場機會。然而，高昂的治療成本可能對市場擴張構成挑戰。

抗真菌藥物市場-關鍵見解

根據我們的研究分析師分享的分析，預計全球市場在預測期內（2024-2032 年）每年將以 3.79% 左右的複合年成長率成長

根據藥物類別細分，預計唑類藥物將在 2023 年佔據最大市場佔有率

根據適應症細分，念珠菌病是2023年的主導類型

根據給藥途徑細分，2023年口服是領先類型

依感染類型細分，2023年全身性抗黴菌感染為主導類型

從配銷通路細分來看，醫院藥局是2023年的主導類型

按地區分類，北美是 2023 年的主要收入來源

抗真菌藥物市場-細分分析：

全球抗真菌藥物市場根據藥物類別、適應症、給藥途徑、感染類型、配銷通路和地區進行細分。

根據藥物類別，市場分為三類：唑類、棘白菌素類、多烯類、烯丙胺類和其他。唑類在市場上佔主導地位。這類抗真菌藥物廣泛用於治療多種真菌感染。它們的作用機制涉及抑制麥角固醇的合成（真菌細胞膜的關鍵元素），導致真菌最終死亡。

根據適應症，市場分為三類：皮癬菌病、麴菌病、念珠菌病和其他。念珠菌病在市場上佔據主導地位。這種由念珠菌引起的疾病是一種普遍的真菌感染，可以表現為淺層和全身的侵襲性形式。念珠菌病抗真菌藥物的選擇受到感染的嚴重程度和部位以及患者特定因素（包括免疫狀態和先前治療）的影響。

根據給藥途徑，市場分為三個部分：口服、外用和注射。口服細分市場引領市場。口服抗真菌藥物用於治療口腔內的真菌感染，通常稱為口腔念珠菌病或鵝口瘡。

根據感染類型，市場分為兩個部分：全身性抗真菌感染和表淺抗真菌感染。全身性抗真菌感染藥物在市場上佔據主導地位。全身性抗真菌感染的治療對於解決嚴重真菌感染至關重要，需要根據特定的真菌病原體和患者的病情選擇合適的抗真菌藥物。

根據分銷管道，市場分為兩個部分：醫院藥房、零售藥房等。醫院藥房在市場上佔據主導地位。他們的任務是選擇、準備和服用藥物，從而確保有效和安全的治療。

抗真菌藥物市場-地理洞察

市場地域廣闊，涵蓋北美、拉丁美洲、歐洲、亞太地區、中東和非洲。這些領域根據對商業活動做出貢獻的國家進一步分類。北美憑藉其先進的醫療基礎設施和高品質的醫療設施引領市場。尤其是美國，擁有高度發展的醫療保健體系，擁有先進的醫院、研究機構和診斷中心。先進的醫療設施，包括專門的傳染病中心，有助於及時、準確地診斷真菌感染。最近的資料和報告表明，2021年美國醫療保健總支出預計將達到4.3兆美元，佔該國GDP的18.5%。在政府和私營部門投資增加的推動下，歐洲成為市場成長的第二大地區。

抗真菌藥物市場-競爭格局：

抗真菌藥物市場的競爭格局受到多種因素的影響，包括藥物的有效性、安全性、配方的進步和定價策略。各組織分配大量資源用於研究和開發，旨在發現新型抗真菌化合物、增強現有配方並解決與抗藥性相關的問題。主要競爭要素包括藥物輸送系統的創新、聯合療法以及新型抗真菌藥物的推出。公司努力擴大其地理分佈，特別是在真菌感染構成重大挑戰的新興市場。建立市場佔有率的常見策略包括建立策略合作夥伴關係、尋求收購以及參與本地製造。專注於開發抗藥性菌株治療方法或提供新治療選擇的公司可能會在市場上獲得更強大的地位。

最新進展：

2023年8月，全球學名藥和生物相似藥領域的知名企業山德士宣布成功收購安斯泰來著名全身抗真菌藥物Mycamine（米卡芬淨鈉，日本稱為Funguard）的全球品牌權。

目錄

第1章：抗真菌藥物市場概述

  • 研究範圍
  • 市場預估年份

第 2 章：執行摘要

  • 市場片段
    • 按藥物類別分類的抗真菌藥物市場片段
    • 按適應症分類的抗真菌藥物市場片段
    • 按給藥途徑分類的抗黴菌藥物市場片段
    • 按感染類型分類的抗真菌藥物市場片段
    • 按配銷通路分類的抗真菌藥物市場片段
    • 按國家/地區分類的抗真菌藥物市場片段
    • 按地區分類的抗真菌藥物市場片段
  • 競爭洞察

第 3 章：抗真菌藥物主要市場趨勢

  • 抗真菌藥物市場促進因素
    • 市場促進因素的影響分析
  • 抗真菌藥物市場限制
    • 市場限制影響分析
  • 抗真菌藥物市場機會
  • 抗真菌藥物市場未來趨勢

第 4 章：抗真菌藥物產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第 5 章：抗真菌藥物市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長市場區隔
    • 最寬鬆的市場區隔
    • 邊際損失市場區隔

第 6 章：抗黴菌藥物市場格局

  • 2023 年抗真菌藥物市場佔有率分析
  • 按主要製造商分類的故障數據
    • 既有參與者分析
    • 新興參與者分析

第 7 章：抗真菌藥物市場 - 按藥物類別

  • 概述
    • 按藥物類別分類的細分市場佔有率分析
    • 唑類
    • 棘白菌素
    • 多烯
    • 烯丙胺
    • 其他

第 8 章：抗真菌藥物市場 - 按適應症

  • 概述
    • 按指標分類的細分市場佔有率分析
    • 皮癬菌病
    • 麴菌病
    • 念珠菌病
    • 其他

第 9 章：抗真菌藥物市場 - 按給藥途徑

  • 概述
    • 按給藥途徑分類的細分市場佔有率分析
    • 口服
    • 專題
    • 可注射

第 10 章：抗真菌藥物市場 - 按感染類型

  • 概述
    • 按指標分類的細分市場佔有率分析
    • 全身抗黴菌感染
    • 表層抗真菌感染

第 11 章：抗真菌藥物市場 - 按配銷通路

  • 概述
    • 按配銷通路分類的細分市場佔有率分析
    • 醫院藥房
    • 零售藥局
    • 其他

第 12 章：抗黴菌藥物市場 - 按地理位置

  • 介紹
    • 按地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美抗真菌藥物主要製造商
    • 北美市場規模和預測（按國家）
    • 北美市場規模和預測（按藥物類別）
    • 北美市場規模和預測（按指標）
    • 北美市場規模與預測（按管理途徑）
    • 北美市場規模和預測（按感染類型）
    • 北美市場規模和預測（按配銷通路）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲抗真菌藥物主要製造商
    • 歐洲市場規模和預測（按國家）
    • 歐洲市場規模和預測（按藥物類別）
    • 歐洲市場規模與預測（按指標）
    • 歐洲市場規模與預測（按管理途徑）
    • 歐洲市場規模和預測（按感染類型）
    • 歐洲市場規模和預測（按配銷通路）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區抗真菌藥物主要製造商
    • 亞太地區市場規模與預測（按國家）
    • 亞太地區市場規模和預測（按藥物類別）
    • 亞太地區市場規模與預測（依指標）
    • 亞太地區市場規模與預測（依管理途徑）
    • 亞太地區市場規模和預測（按感染類型）
    • 亞太地區市場規模和預測（按配銷通路）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲抗真菌藥物主要製造商
    • 拉丁美洲市場規模與預測（按國家）
    • 拉丁美洲市場規模與預測（按藥物類別）
    • 拉丁美洲市場規模與預測（按指標）
    • 拉丁美洲市場規模與預測（按管理途徑）
    • 拉丁美洲市場規模與預測（按感染類型）
    • 拉丁美洲市場規模和預測（按配銷通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲抗真菌藥物主要製造商
    • 中東和非洲市場規模及預測（按國家）
    • 中東和非洲市場規模及預測（按藥物類別）
    • 中東和非洲市場規模及預測（依指標）
    • 中東和非洲市場規模及預測（按管理途徑）
    • 中東和非洲市場規模及預測（按感染類型）
    • 中東和非洲市場規模及預測（按配銷通路）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 的其餘部分

第 13 章：主要供應商分析 - 抗真菌藥物產業

  • 競爭儀表板
  • 公司簡介
    • Novartis AG
    • Pfizer, Inc.
    • Bayer AG
    • Sanofi
    • Merck & Co., Inc.
    • GlaxoSmithKline plc
    • Abbott
    • Glenmark
    • Enzon Pharmaceuticals, Inc.
    • Astellas Pharma, Inc.
    • Others

第 14 章：360 度分析師視角

第 15 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV3627

REPORT HIGHLIGHT

Antifungal Drugs Market size was valued at USD 15,678.23 Million in 2023, expanding at a CAGR of 3.79% from 2024 to 2032.

Antifungal medications are utilized to address fungal infections. Fungi present in the soil, air, and on the skin can result in conditions such as yeast infections, ringworm, and infections affecting the nails and skin. Inhalation of fungal spores may result in respiratory ailments. Individuals with compromised immune systems are at a higher risk for fungal infections that necessitate antifungal treatment. A range of antifungal drugs is available to combat these infections, with some being accessible over the counter while others require a prescription, contingent upon the specific medication.

Antifungal Drugs Market- Market Dynamics

The growing prevalence of fungal infections is anticipated to drive the growth of the market

Fungal infections, including candidiasis, aspergillosis, and cryptococcosis, are increasingly prevalent, especially among individuals with compromised immune systems, such as those suffering from HIV/AIDS, cancer, or those who have undergone organ transplants. The rising frequency of these infections, along with enhanced awareness and the availability of diagnostic tools, is driving the demand for effective antifungal therapies. According to the Centers for Disease Control and Prevention, over 75,000 hospitalizations and nearly 9 million outpatient visits for fungal diseases occur annually. Additionally, ongoing research and development in antifungal treatments, which includes the identification of new drug classes and innovative formulations, present substantial market opportunities. Nevertheless, the high cost of treatment may pose a challenge to market expansion.

Antifungal Drugs Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 3.79% over the forecast period (2024-2032)

Based on Drug Class segmentation, Azoles was predicted to show maximum market share in the year 2023

Based on Indication segmentation, Candidiasis was the leading type in 2023

Based on Route of Administration segmentation, Oral was the leading type in 2023

Based on Infection Type segmentation, Systemic antifungal infections were the leading type in 2023

Based on Distribution Channel segmentation, Hospital pharmacies were the leading type in 2023

Based on region, North America was the leading revenue generator in 2023

Antifungal Drugs Market- Segmentation Analysis:

The Global Antifungal Drugs Market is segmented based on Drug Class, Indication, Route of Administration, Infection Type, Distribution Channel, and Region.

The market is segmented into three categories according to Drug Class: Azoles, Echinocandins, Polyenes, Allylamines, and Others. Azoles hold a dominant position in the market. This class of antifungal medications is widely utilized for the treatment of numerous fungal infections. Their mechanism of action involves the inhibition of ergosterol synthesis, a crucial element of fungal cell membranes, resulting in the eventual demise of the fungus.

The market is segmented into three categories according to Indication: Dermatophytosis, Aspergillosis, Candidiasis, and Others. Candidiasis holds a predominant position in the market. This condition, resulting from Candida species, represents a prevalent fungal infection that can manifest in both superficial and systemic, invasive forms. The selection of antifungal medications for candidiasis is influenced by the severity and location of the infection, as well as patient-specific factors, including immune status and previous treatments.

The market is classified into three segments according to Route of administration: Oral, Topical, and Injectable. The Oral segment leads the market. Oral antifungal medications are utilized to address fungal infections within the oral cavity, frequently referred to as oral candidiasis or thrush.

The market is categorized into two segments according to Infection Type: Systemic antifungal infections and superficial antifungal infections. Systemic antifungal infections hold a predominant position in the market. The treatment of systemic antifungal infections is crucial for addressing severe fungal infections and requires the selection of a suitable antifungal agent based on the specific fungal pathogen and the patient's condition.

The market is categorized into two segments based on Distribution Channels: Hospital pharmacies, Retail pharmacies, and others. Hospital pharmacies hold a dominant position in the market. They are tasked with the selection, preparation, and administration of medications, thereby ensuring both effective and safe treatment.

Antifungal Drugs Market- Geographical Insights

This market is geographically extensive, encompassing North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These areas are further categorized based on the countries contributing to business activities. North America leads the market, attributed to its advanced healthcare infrastructure and high-quality medical facilities. The United States, in particular, features a highly developed healthcare system, equipped with cutting-edge hospitals, research institutions, and diagnostic centers. The presence of advanced medical facilities, including specialized centers for infectious diseases, facilitates prompt and precise diagnosis of fungal infections. Recent data and reports indicate that total healthcare expenditure in the United States for 2021 is projected to reach USD 4.3 trillion, representing 18.5% of the nation's GDP. Europe ranks as the second-largest region for market growth, driven by increased investments from both government and private sectors.

Antifungal Drugs Market- Competitive Landscape:

The competitive landscape of the antifungal drugs market is influenced by various factors, including the effectiveness of medications, safety profiles, advancements in formulations, and pricing strategies. Organizations allocate substantial resources to research and development aimed at discovering novel antifungal compounds, enhancing current formulations, and tackling issues related to drug resistance. Key competitive elements include innovations in drug delivery systems, combination therapies, and the introduction of new classes of antifungal agents. Companies strive to broaden their geographical presence, particularly in emerging markets where fungal infections pose a significant challenge. Common strategies for establishing a market presence include forming strategic partnerships, pursuing acquisitions, and engaging in local manufacturing. Firms that concentrate on developing treatments for resistant strains or providing new therapeutic options are likely to achieve a stronger position in the market.

Recent Developments:

In August 2023, Sandoz, a prominent global entity in the field of generic and biosimilar pharmaceuticals, announced the successful acquisition of the global brand rights for the renowned systemic antifungal medication Mycamine (micafungin sodium, known as Funguard in Japan) from Astellas.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ANTIFUNGAL DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Novartis AG
  • Pfizer, Inc.
  • Bayer AG
  • Sanofi
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Abbott
  • Glenmark
  • Enzon Pharmaceuticals, Inc.
  • Astellas Pharma, Inc.
  • Others

GLOBAL ANTIFUNGAL DRUGS MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Azoles
  • Echinocandins
  • Polyenes
  • Allylamines
  • Others

GLOBAL ANTIFUNGAL DRUGS MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Dermatophytosis
  • Aspergillosis
  • Candidiasis
  • Others

GLOBAL ANTIFUNGAL DRUGS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Topical
  • Injectable

GLOBAL ANTIFUNGAL DRUGS MARKET, BY INFECTION TYPE- MARKET ANALYSIS, 2019 - 2032

  • Systemic antifungal infections
  • Superficial antifungal infections

GLOBAL ANTIFUNGAL DRUGS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital pharmacies
  • Retail pharmacies
  • Others

GLOBAL ANTIFUNGAL DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Antifungal Drugs Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Antifungal Drugs Market Snippet by Drug Class
    • 2.1.2. Antifungal Drugs Market Snippet by Indication
    • 2.1.3. Antifungal Drugs Market Snippet by Route of Administration
    • 2.1.4. Antifungal Drugs Market Snippet by Infection Type
    • 2.1.5. Antifungal Drugs Market Snippet by Distribution Channel
    • 2.1.6. Antifungal Drugs Market Snippet by Country
    • 2.1.7. Antifungal Drugs Market Snippet by Region
  • 2.2. Competitive Insights

3. Antifungal Drugs Key Market Trends

  • 3.1. Antifungal Drugs Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Antifungal Drugs Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Antifungal Drugs Market Opportunities
  • 3.4. Antifungal Drugs Market Future Trends

4. Antifungal Drugs Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Antifungal Drugs Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Antifungal Drugs Market Landscape

  • 6.1. Antifungal Drugs Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Antifungal Drugs Market - By Drug Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
    • 7.1.2. Azoles
    • 7.1.3. Echinocandins
    • 7.1.4. Polyenes
    • 7.1.5. Allylamines
    • 7.1.6. Others

8. Antifungal Drugs Market - By Indication

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Indication, 2023 & 2032 (%)
    • 8.1.2. Dermatophytosis
    • 8.1.3. Aspergillosis
    • 8.1.4. Candidiasis
    • 8.1.5. Others

9. Antifungal Drugs Market - By Route of Administration

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 9.1.2. Oral
    • 9.1.3. Topical
    • 9.1.4. Injectable

10. Antifungal Drugs Market - By Infection Type

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Infection, 2023 & 2032 (%)
    • 10.1.2. Systemic antifungal infections
    • 10.1.3. Superficial antifungal infections

11. Antifungal Drugs Market - By Distribution Channel

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
    • 11.1.2. Hospital pharmacies
    • 11.1.3. Retail pharmacies
    • 11.1.4. Others

12. Antifungal Drugs Market- By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. Antifungal Drugs Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.2.9. U.S.
      • 12.2.9.1. Overview
      • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.9.3. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.2.9.4. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.2.9.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.9.6. U.S. Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.2.9.7. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.2.10. Canada
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.10.3. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.2.10.4. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.2.10.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.10.6. Canada Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.2.10.7. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. Antifungal Drugs Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.9. Germany
      • 12.3.9.1. Overview
      • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.9.3. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.3.9.4. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.9.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.9.6. Germany Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.3.9.7. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.10. Italy
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.10.3. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.3.10.4. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.10.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.10.6. Italy Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.3.10.7. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.11. United Kingdom
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.11.3. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.3.11.4. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.11.5. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.11.6. United Kingdom Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.3.11.7. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.12. France
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.12.3. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.3.12.4. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.12.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.12.6. France Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.3.12.7. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.13. Russia
      • 12.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.13.2. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.3.13.3. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.13.4. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.13.5. Russia Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.3.13.6. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.14. Netherlands
      • 12.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.14.2. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.3.14.3. Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.14.4. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.14.5. Netherlands Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.3.14.6. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.15. Sweden
      • 12.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.15.2. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.3.15.3. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.15.4. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.15.5. Sweden Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.3.15.6. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.16. Poland
      • 12.3.16.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.16.2. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.3.16.3. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.16.4. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.16.5. Poland Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.3.16.6. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.17. Rest of Europe
      • 12.3.17.1. Overview
      • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.17.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.3.17.4. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.3.17.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.17.6. Rest of the Europe Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.3.17.7. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. Antifungal Drugs Key Manufacturers in Asia Pacific
    • 12.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.4.5. Asia Pacific Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 12.4.6. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.4.7. Asia Pacific Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 12.4.8. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.9. India
      • 12.4.9.1. Overview
      • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.9.3. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.4.9.4. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.9.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.9.6. India Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.4.9.7. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.10. China
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.10.3. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.4.10.4. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.10.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.10.6. China Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.4.10.7. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.11. Japan
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.11.3. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.4.11.4. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.11.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.11.6. Japan Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.4.11.7. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.12. South Korea
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.12.3. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.4.12.4. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.12.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.12.6. South Korea Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.4.12.7. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.13. Australia
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.13.3. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.4.13.4. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.13.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.13.6. Australia Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.4.13.7. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.14. Thailand
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.14.3. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.4.14.4. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.14.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.14.6. Thailand Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.4.14.7. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.15. Indonesia
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.15.3. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.4.15.4. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.15.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.15.6. Indonesia Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.4.15.7. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.16. Philippines
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.16.3. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.4.16.4. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.16.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.16.6. Philippines Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.4.16.7. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.17. Rest of APAC
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.17.3. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.4.17.4. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.4.17.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.17.6. Rest of APAC Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.4.17.7. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.5. Latin America
    • 12.5.1. Overview
    • 12.5.2. Antifungal Drugs Key Manufacturers in Latin America
    • 12.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.5.4. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.5.5. Latin America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 12.5.6. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.5.7. Latin America Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 12.5.8. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.9. Brazil
      • 12.5.9.1. Overview
      • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.9.3. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.5.9.4. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.5.9.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.9.6. Brazil Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.5.9.7. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.10. Mexico
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.10.3. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.5.10.4. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.5.10.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.10.6. Mexico Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.5.10.7. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.11. Argentina
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.11.3. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.5.11.4. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.5.11.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.11.6. Argentina Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.5.11.7. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.12. Colombia
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.12.3. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.5.12.4. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.5.12.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.12.6. Colombia Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.5.12.7. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.13. Rest of LATAM
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.13.6. Rest of LATAM Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.5.13.7. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. Antifungal Drugs Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.9. Saudi Arabia
      • 12.6.9.1. Overview
      • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.9.6. Saudi Arabia Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.6.9.7. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.10. United Arab Emirates
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.10.6. United Arab Emirates Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.6.10.7. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.11. Israel
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.11.3. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.6.11.4. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.6.11.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.11.6. Israel Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.6.11.7. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.12. Turkey
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.12.3. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.6.12.4. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.6.12.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.12.6. Turkey Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.6.12.7. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.13. Algeria
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.13.3. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.6.13.4. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.6.13.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.13.6. Algeria Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.6.13.7. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.14. Egypt
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.14.3. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.6.14.4. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.6.14.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.14.6. Egypt Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.6.14.7. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.15. Rest of MEA
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.15.3. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.6.15.4. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 12.6.15.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.15.6. Rest of MEA Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
      • 12.6.15.7. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Antifungal Drugs Industry

  • 13.1. Competitive Dashboard
  • 13.2. Company Profiles
    • 13.2.1. Novartis AG
    • 13.2.2. Pfizer, Inc.
    • 13.2.3. Bayer AG
    • 13.2.4. Sanofi
    • 13.2.5. Merck & Co., Inc.
    • 13.2.6. GlaxoSmithKline plc
    • 13.2.7. Abbott
    • 13.2.8. Glenmark
    • 13.2.9. Enzon Pharmaceuticals, Inc.
    • 13.2.10. Astellas Pharma, Inc.
    • 13.2.11. Others

14. 360 Degree Analyst View

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us